| Literature DB >> 28850583 |
Kolsoum InanlooRahatloo1,2,3, Grace Liang1, Davis Vo1, Antje Ebert1, Ivy Nguyen1, Patricia K Nguyen1,2,4,5.
Abstract
Sex differences in the development of the normal heart and the prevalence of cardiomyopathies have been reported. The molecular basis of these differences remains unclear. Sex differences in the human heart might be related to patterns of gene expression. Recent studies have shown that sex specific differences in gene expression in tissues including the brain, kidney, skeletal muscle, and liver. Similar data is limited for the heart. Herein we address this issue by analyzing donor and post-mortem adult human heart samples originating from 46 control individuals to study whole-genome gene expression in the human left ventricle. Using data from the genotype tissue expression (GTEx) project, we compared the transcriptome expression profiles of male and female hearts. We found that genes located on sex chromosomes were the most abundant ones among the sexually dimorphic genes. The majority of differentially expressed autosomal genes were those involved in the regulation of inflammation, which has been found to be an important contributor to left ventricular remodeling. Specifically, genes on autosomal chromosomes encoding chemokines with inflammatory functions (e.g. CCL4, CX3CL1, TNFAIP3) and a gene that regulates adhesion of immune cells to the endothelium (e.g., VCAM1) were identified with sex-specific expression levels. This study underlines the relevance of sex as an important modifier of cardiac gene expression. These results have important implications in the understanding of the differences in the physiology of the male and female heart transcriptome and how they may lead to different sex specific difference in human cardiac health and its control.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28850583 PMCID: PMC5574577 DOI: 10.1371/journal.pone.0183874
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Demographic and clinical variables of cohort.
| All Groups | Young (<55 years old) | Old (≥ 55 years old) | |||||
|---|---|---|---|---|---|---|---|
| Demographic | Male (n = 29) | Female (n = 17) | Male (n = 25) | Female (n = 10) | Male (n = 4) | Female (n = 7) | |
| Age (years) | 42.7±13.3 | 50.5±14.0 | 40.0±11.9 | 42.5±12.8 | 60.7±4.3 | 61.9±4.7 | |
| Caucasian (%) | 96.7 | 82.4 | 96 | 80 | 100 | 85.7 | |
| BMI (kg/m2) | 26.8±4.1 | 26.2±3.9 | 26.±4.4 | 28.1±4.2 | 27.8±2.2 | 23.6±1.1 | |
| Hypertension | 27 (8/29) | 47 (8/17) | 20(5/25) | 50(5/10) | 75(3/4) | 43(3/7) | |
| Heart disease | 0 | 0 | 0 | 0 | 0 | 0 | |
| COPD/Asthma | 20(6/29) | 6(1/17) | 24(6/25) | 10(1/10) | 0 | 0 | |
| Autoimmune, inflammatory, or infectious disease | 12(3/29) | 0 | 8(2/25) | 0 | 25(1/4) | 0 | |
| Kidney disease | 0 | 6(1/17) | 0 | 0 | 0 | 10(1/7) | |
| Steroid use | 0 | 0 | 0 | 0 | 0 | 0 | |
| Hemorrhage | 23(7/29) | 29(5/17) | 24(6/25) | 50(5/10) | 25(1/4) | 0 | |
| Blunt injury | 6(2/29) | 12(2/17) | 4(1/25) | 10(1/10) | 25(1/4) | 14(1/7) | |
| SIGSW | 6(2/29) | 0 | 8(2/25) | 0 | 0 | 0 | |
| EtOH abuse | 3(1/29) | 0 | 4(1/25) | 0 | 0 | 0 | |
| Hepatorenal syndrome | 3(1/29) | 0 | 4(1/25) | 0 | 0 | 0 | |
| Shock secondary to burns | 3(1/29) | 0 | 4(1/25) | 0 | 0 | 0 | |
| Trauma | 6(2/29) | 6(1/17) | 8(2/25) | 10(1/10) | 0 | 0 | |
| Smoke inhalation-respiratory disease | 3(1/29) | 0 | 4(1/25) | 0 | 0 | 0 | |
| Hanging | 12(3/29) | 6(1/17) | 8(2/25) | 10(1/10) | 25(1/4) | 0 | |
| Drug intoxication | 12(3/29) | 0 | 8(2/25) | 0 | 25(1/4) | 0 | |
| Trauma | 6(2/29) | 6(1/17) | 8(2/25) | 10(1/10) | 0 | 0 | |
| Asphyxiation | 6(2/29) | 6(1/17) | 8(2/25) | 0 | 0 | 14(1/7) | |
| Seizure | 3(1/29) | 0 | 4(1/25) | 0 | 0 | 0 | |
| Drug overdose | 0 | 18(3/17) | 0 | 10(1/10) | 0 | 29(2/7) | |
| Complications from ALS | 0 | 6(1/17) | 0 | 0 | 0 | 14(1/7) | |
| Liver transplant | 0 | 6(1/17) | 0 | 0 | 0 | 14(1/7) | |
| Not available | 0 | 6(1/17) | 0 | 0 | 0 | 14(1/7) | |
ALS, amyotrophic lateral sclerosis; MVA, motor vehicle accident; SAH, subarachnoid hemorrhage; SIGSW, survivors of self-inflicted gunshot wound.
Fig 1Chromosomal enrichment.
For each chromosome, the number of male- and female-biased genes was computed, the table below the graph lists chromosomes that passed the test for enrichment by Fisher exact test with Benjamini correction, P < 0.05.
Fig 2Differentially expressed genes heat map.
Heat map showing differentially expressed genes between male and female LV tissues.
Age and sex stratified comparisons of differentially expressed genes, q value <0.05 and fold change > 1.5.
| Sex-Dependent Differences | Absolute Fold Change | Differentially Expressed Genes | Female-Biased Genes | Male-Biased Genes |
|---|---|---|---|---|
| 138 | 105 | 33 | ||
| 22 | 17 | 5 | ||
| 18 | 2 | 16 | ||
| 5 | 4 | 1 | ||
| 9 | 7 | 2 | ||
| 20 | 4 | 16 | ||
| 9 | 3 | 6 | ||
| 6 | 3 | 3 | ||
| 22 | 4 | 18 |
Biological functions associated with female biased genes.
| Network | Top Functions | p Value | Genes |
|---|---|---|---|
| Diseases and disorders | |||
| 1 | Inflammatory response | 4.70E-03–1.08E-08 | 50 |
| 2 | Inflammatory disease | 4.67E-03–1.39E-07 | 31 |
| 3 | Cancer | 4.66E-03–2.35E-07 | 110 |
| 4 | Gastrointestinal disease | 4.67E-03–2.35E-07 | 101 |
| 5 | Organismal injury and abnormalities | 4.67E-03–2.35E-07 | 111 |
| Molecular and cellular functions | |||
| 1 | Cellular movement | 4.70E-03–3.85E-11 | 44 |
| 2 | Cell-to-cell signaling and interaction | 4.40E-03–1.93E-08 | 35 |
| 3 | Cell death and survival | 4.70E-03–4.11E-07 | 50 |
| 4 | Cell morphology | 3.34E-03–2.03E-06 | 28 |
| 5 | Cellular growth and proliferation | 4.69E-03–1.48E-05 | 49 |
| Physiological system development and function | |||
| 1 | Hematological system development and function | 4.70E-03–3.85E-11 | 40 |
| 2 | Immune cell trafficking | 4.70E-03–3.85E-11 | 33 |
| 3 | Cell-mediated immune response | 4.70E-03–2.85E-08 | 19 |
| 4 | Tissue morphology | 4.70E-03–1.63E-07 | 43 |
| 5 | Cardiovascular system development and function | 3.34E-03–2.10E-07 | 29 |
Biological functions associated with male biased genes.
| Network | Top Functions | p Value | Genes |
|---|---|---|---|
| Disease and disorders | |||
| 1 | Respiratory disease | 1.33E-02–1.47E-04 | 6 |
| 2 | Connective tissue disorders | 4.58E-02–2.03E-03 | 5 |
| 3 | Skeletal and muscular disorders | 4.10E-02–2.03E-03 | 6 |
| 4 | Cancer | 4.58E-02–2.03E-03 | 5 |
| 5 | Muscular disorders | 4.10E-02–2.03E-03 | 6 |
| Molecular and cellular functions | |||
| 1 | Cell morphology | 4.80E-02–2.16E-04 | 13 |
| 2 | Cell cycle | 4.58E-02–3.74E-04 | 3 |
| 3 | Cell death and survival | 4.58E-02–7.28E-04 | 5 |
| 4 | Cell-to-cell signaling and interaction | 4.58E-02–2.23E-03 | 8 |
| 5 | Cellular assembly and organization | 4.58E-02–2.23E-03 | 7 |
| Physiological system development and function | |||
| 1 | Connective tissue development and function | 4.58E-02–2.16E-04 | 5 |
| 2 | Organismal development | 4.58E-02–2.16E-04 | 10 |
| 3 | Tissue morphology | 4.80E-02–2.16E-04 | 14 |
| 4 | Auditory and vestibular system development and function | 4.37E-02–2.23E-03 | 2 |
| 5 | Embryonic development | 4.37E-02–2.23E-03 | 9 |
Female up-regulated genes in inflammatory and heart development pathways.
| Term | P-value | Adjusted P-value | Z-score | Combined Score | Genes |
|---|---|---|---|---|---|
| Regulation of leukocyte activation (GO:0002694) | 5.27207E-06 | 0.004336 | -2.5289 | 13.75908 | SPN; LAG3; CD83; VCAM1; CCL21; FOXF1; FES; CCL5; ZC3H12A; TNFAIP3; THY1; TNFRSF4 |
| Regulation of cytokine production (GO:0001817) | 4.10711E-05 | 0.011260 | -2.4979 | 11.20706 | SPN; NFKBIA; AFAP1L2; LAG3; CD83; ZC3H12A; CASP1; TNFAIP3; TNFRSF4; CX3CL1; MB21D1; MAPK13 |
| Taxis (GO:0042330) | 3.90027E-05 | 0.011260 | -2.3959 | 10.74952 | SPN; VCAM1; CCL21; CCL5; CCL4; CXCL1; SLIT3; TREM1; CX3CL1 |
| Chemotaxis (GO:0006935) | 3.90027E-05 | 0.011260 | -2.3933 | 10.73764 | SPN; VCAM1; CCL21; CCL5; CCL4; CXCL1; SLIT3; TREM1; CX3CL1 |
| Cell chemotaxis (GO:0060326) | 5.62173E-05 | 0.013211 | -2.2419 | 9.699928 | VCAM1; CCL21; CCL5; CCL4; CXCL1; TREM1; CX3CL1 |
| Negative regulation of immune system process (GO:0002683) | 0.00013572 | 0.020580 | -2.4380 | 9.467821 | SPN; NFKBIA; LAG3; CCL21; FOXF1; ZC3H12A; TNFAIP3; THY1; NBL1 |
| Regulation of inflammatory response (GO:0050727) | 0.000155026 | 0.021251 | -2.4038 | 9.257948 | SPN; FOXF1; CCL5; CASP1; TNFAIP3; CX3CL1; CFB; MAPK13 |
| Inflammatory response (GO:0006954) | 0.000111624 | 0.020402 | -2.3622 | 9.193863 | AOC3; AFAP1L2; VCAM1; CCL21; CCL5; CCL4; TNFAIP3; CXCL1; TNFRSF4; PTGES |
| Regulation of immune effector process (GO:0002697) | 0.000240717 | 0.030460 | -2.4394 | 8.51707 | SPN; LAG3; FOXF1; FES; TNFAIP3; TNFRSF4; CFB; MB21D1 |
| Regulation of lymphocyte activation (GO:0051249) | 0.000282146 | 0.032930 | -2.4716 | 8.436548 | SPN; LAG3; CD83; VCAM1; CCL21; CCL5; TNFAIP3; THY1; TNFRSF4 |
Fig 3Female heart over expressed genes involve in inflammatory pathways.
The bar graphs show the read count and error bars represent standard deviation.
Five top canonical pathways for female and male biased genes.
| Granulocyte adhesion and diapedesis | 5.17E-05 | 4.0% (7/177) |
| Agranulocyte adhesion and diapedesis | 7.81E-05 | 3.7% (7/189) |
| Differential regulation of cytokine production in macrophages and T helper cells by IL-17A and IL-17F | 1.20E-04 | 16.7% (3/18) |
| Role of IL-17A in arthritis | 2.11E-04 | 7.4% (4/54) |
| Differential regulation of cytokine production in intestinal epithelial cells by IL-17A and IL- 17F | 2.55E-04 | 13.0% (3/23) |
| Hepatic fibrosis / hepatic stellate cell activation | 7.31E-04 | 2.2% (4/183) |
| Pancreatic adenocarcinoma signaling | 1.71E-03 | 2.8% (3/106) |
| Glutathione biosynthesis | 6.68E-03 | 33.3% (1/3) |
| ILK Signaling | 8.12E-03 | 1.6% (3/185) |
| LPS/IL-1 mediated inhibition of RXR function | 1.30E-02 | 1.4% (3/220) |
Top biological functions, molecular functions and cellular components of female biased genes.
| Female-Biased Genes | P-value | Adjusted p-value | Z-score |
|---|---|---|---|
| Regulation of cell adhesion (GO:0030155) | 1.185E-06 | 0.0019494 | -2.4626837 |
| Regulation of leukocyte activation (GO:0002694) | 5.2721E-06 | 0.00433628 | -2.528899 |
| Regulation of cell activation (GO:0050865) | 1.0921E-05 | 0.00598837 | -2.5255131 |
| Regulation of cytokine production (GO:0001817) | 4.1071E-05 | 0.01126033 | -2.4979698 |
| Mesodermal cell differentiation (GO:0048333) | 0.00013762 | 0.02058018 | -2.7762975 |
| Chemokine activity (GO:0008009) | 2.2994E-05 | 0.00738119 | -2.4379607 |
| CCR chemokine receptor binding (GO:0048020) | 0.00029438 | 0.0314983 | -3.1141924 |
| Chemokine receptor binding (GO:0042379) | 5.4359E-05 | 0.0087247 | -2.2605308 |
| Side of membrane (GO:0098552) | 1.8363E-05 | 0.00131292 | -2.2865759 |
| External side of plasma membrane (GO:0009897) | 2.9874E-05 | 0.00142397 | -2.2381773 |
| Extracellular space (GO:0005615) | 1.3675E-05 | 0.00131292 | -2.2091901 |
5 top MGI mammalian phenotype for female biased genes.
| Female-Biased Genes | P-value | Adjusted P-value | Z-score |
|---|---|---|---|
| Abnormal innate immunity | 0.0002497 | 0.016636772 | -1.6699686 |
| Abnormal adaptive immunity | 8.7305E-05 | 0.009906402 | -1.3827691 |
| Abnormal immune cell | 9.2153E-05 | 0.009906402 | -1.3722959 |
Fig 4Transcription factor binding sites.
Transcription factor binding site analysis comparing male-biased and female-biased genes in human LV tissue.
Fig 5Associations between DEGs and predicted TFs.
Diagram of the network of predicted associations between DEGs and predicted TFs (KLF4 and NF-kappa B). The network nodes are proteins. The edges represent the predicted functional associations.